Mesoblast GAAP EPS of -$0.04 beats by $0.08, revenue of $120.25M misses by $65.62M (NASDAQ:MESO)
Mesoblast reported FY GAAP EPS of -$0.04, beating estimates by $0.08, while revenue of $120.25M missed by $65.62M. Revenue grew 599.1% year-over-year. The company also received FDA approval for a new potency assay for Ryoncil.
How this was made
The 30-second read
Why it matters
The recap reinforces the negative revenue surprise, likely sustaining any recent price decline.
Market read
Limited to Mesoblast shareholders; no broader market catalyst.
What to watch
Potential upcoming FDA approval for Ryoncil assay could offset short‑term revenue disappointment.
Background
Mesoblast's Q4 2026 results were originally released on 2026‑08‑27. The article merely repeats those figures without new guidance or events.
Ticker impact
The article recaps Mesoblast's FY GAAP EPS of -$0.04 beating expectations and revenue of $120.25M missing by $65.62M, numbers already released 48 days earlier.
downward pressure as investors focus on the sizable revenue shortfall.
Even though EPS beat, the large revenue miss is material for a biotech with limited cash flow, prompting sell‑offs.
Market effects
May dampen sentiment toward small‑cap biotech earnings, reinforcing caution on similar companies.
Limited to US biotech investors; no broader regional effect.
Low; the story is company‑specific without macro implications.
Counterpoint
Investors could view the EPS beat as a sign of cost control and hold through the revenue miss.
Key entities
- companyMesoblast Limited
Biotech firm listed on NASDAQ under ticker MESO.
